Why I might buy this soaring stock alongside the Glaxo (GSK) share price

I say GlaxoSmithKline (LON: GSK) is a great investment, but why is this blue-sky biotech making the headlines right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Biotechnology hopefuls come into and go out of fashion from time to time, and the one hitting the headlines at the moment is PureTech Health (LSE: PRTC).

PureTech shares climbed 20% at one point Tuesday, after the share price of Karuna Therapeutics multiplied more than five-fold overnight on the back of a positive clinal trial result. Karuna’s KarXT treatment for schizophrenia is in phase II trials and has reported above-average results, and that’s expected to help clear the way for regulatory approval.

PureTech shares responded with their own gain because the company owns 31.6% of Karuna. PureTech’s holding in Karuna is now worth around $580m, up from $130m last week. To me, it doesn’t look as if the PureTech rise fully incorporates the jump in Karuna’s valuation.

Not to be missed?

Analysts appear to agree, and have been wasting no time in reaffirming their buy ratings on the stock – with Liberum Capital and Peel Hunt among those getting in on the bullish optimism.

According to the perfect markets theory, it’s impossible to get ahead of the market because all new information is instantly available to all players and is immediately factored into share prices. In the wider sense, the theory ignores all sorts of factors that drive share prices, but in this case there could well be a short-term anomaly that hasn’t worked its way through yet.

In the short term, we’ll have to see what happens to the PureTech share price over the next few days, but looking at the bigger picture it seems possible that this could be the breakthrough that puts PureTech on the road to profit – current forecasts for further losses make it otherwise very difficult to value.

Safe cash

If I ever did invest in a blue-sky biotech prospect, it would only be a small amount of cash and it would be alongside a bigger investment in an established pharmaceuticals company like GlaxoSmithKline (LSE: GSK) – to sort of balance the overall risk of investing in the medical field.

Glaxo, in fact, is one of those perpetual Buy stocks that I’ve always seen as a great long-term investment, but I’ve never actually got round to picking up any shares.

Over the past five years I’ve missed a fairly modest 24% gain as the company has really only just started back on the road to earnings growth after having to invest heavily to rebuild its drug development pipeline. But that’s still around twice the performance of the FTSE 100, and Glaxo has been paying annual dividends yielding more than 5% for the period.

Still cheap?

Though the share price has appreciated strongly over the past two years, I still reckon we’re looking at very good value with forward price-to-earnings multiples of around 14 being pretty much bang on the Footsie’s long-term average.

Under the leadership of current chief executive Emma Walmsley, the company is well on its way to transforming itself with a long-term plan to separate its pharmaceuticals and consumer businesses, and I think that’s a sound way forward.

To be fair, there’s not much to choose between Glaxo and FTSE 100 rival AstraZeneca, but I think either should provide great long-term rewards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »